To Improve The Quality And Access To Dialysis Treatments By Indigenous Australians From Remote Areas By Using A Patient-centred Approach To Determine The Cost-effectiveness Of Treatment Models That Include The Health, Social And Economic Impact
Funder
National Health and Medical Research Council
Funding Amount
$1,195,023.00
Summary
Compared to other Australians, Indigenous people from remote areas suffer disproportionately from kidney disease. In order to access treatment they must often relocate, sometimes permanently to urban areas. Communities advocate for services closer to home but most health providers see remote area delivery as prohibitively costly. The study will assess the relative cost-benefits of more patient-centered models of care that are inclusive of impacts on patients, families and communities.
Novel therapies to limit renal fibrosis in diverse models of renal disease. Kidney failure is a devastating health, social and financial outcome for the individual, their employer, family and the broader society, This project will carefully dissect mechanisms underpinning the scarring in the kidney that predisposes to kidney failure and will investigate novel therapies to prevent kidney damage.
The role of SGK-1 and SGK-2 in hypertension and nephropathy in diabetes mellitus. The key objective is to define the suitability of the serum glucocorticoid regulated kinases -1 and -2 (SGK-1, -2) as novel drug discovery targets. A specific inhibitor targeting SGK-1 and -2 will be tested to determine if it reverses the enhanced sodium reabsorption and extracellular matrix production characteristic of progressive renal failure in in vitro models models of renal disease. These inhibitors present a ....The role of SGK-1 and SGK-2 in hypertension and nephropathy in diabetes mellitus. The key objective is to define the suitability of the serum glucocorticoid regulated kinases -1 and -2 (SGK-1, -2) as novel drug discovery targets. A specific inhibitor targeting SGK-1 and -2 will be tested to determine if it reverses the enhanced sodium reabsorption and extracellular matrix production characteristic of progressive renal failure in in vitro models models of renal disease. These inhibitors present an opportunity to control hypertension whilst simultaneously limiting fibrosis in the kidney. Renal failure is steadily increasing and is now the single largest health care cost to the community. These studies will provide the proof of concept required to ultimately bring this novel preventative therapy to the community.Read moreRead less